Company intelligence / Profile preview

PANGAEA

Barcelona, Catalonia, Spain

Ownership: Private
Development stage: Other

Overview

Pangaea Oncology has a strong reputation as a reference lab in precision oncology, leads in molecular diagnostics (especially liquid biopsy), and is developing preclinical oncology assets (PAK inhibitors) with partners. Clinical care is provided through in-house oncology centers.

Therapeutic areas: OncologyWomen's HealthGastroenterology
Modalities: Diagnostic testSmall molecule
Industry: Biotech

Partnerships

Cancer Research Technology (Cancer Research UK)

Beyond the preview

Go deeper on PANGAEA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PANGAEA.

Explore the full profile